Navigation Links
ThromboGenics' Microplasmin Phase III Program Progressing According to Schedule
Date:6/24/2009

i-centre, randomized, placebo controlled, double-masked trials which will evaluate 125micro g of microplasmin versus placebo in the intravitreal treatment of patients with focal vitreomacular adhesion. The trials will enrol a total of approximately 320 patients each across approximately 40 centres in the United States (TG-MV-006) and 40 centres in Europe and North America (TG-MV-007). The safety review was the final of two safety reviews, and had been scheduled to take place after 50% of patients had been enrolled in one of the studies.

The primary endpoint of both trials is the non-surgical resolution of focal vitreomacular adhesion within one month. Additional measures of efficacy and safety will also be assessed at various intervals over six months in both studies. It is estimated that these two studies will be completed by the end of 2010.

Dr. Steve Pakola, Chief Medical Officer of ThromboGenics, commenting on the announcement said, "We are very pleased that the Phase III program for microplasmin is progressing well and that enrolment is on track. We remain confident that microplasmin could potentially make a significant difference to the treatment of back of the eye disease and we very much look forward to reporting the results from these trials."

About ThromboGenics

ThromboGenics is a biotechnology company focused on the discovery and development of innovative biopharmaceuticals for the treatment of eye disease, vascular disease and cancer. The Company's lead product microplasmin is in Phase III clinical development for the non-surgical treatment of back of the eye diseases. Microplasmin is also being evaluated in Phase II clinical development for additional vitreoretinal indications and as a potential therapy for stroke. ThromboGenics is also developing novel antibody therapeutics in collaboration with BioInvent International; these include TB-402 (Anti-Factor VIII), a long acting
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
2. ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin
3. ThromboGenics Begins Phase III Program With Microplasmin for the Non-surgical Treatment of Back of the Eye Disease
4. ThromboGenics and BioInvent Receive Technology Transfer Success Fee From Roche for the Novel Anti-Cancer Antibody, TB-403 (Anti-PIGF)
5. ThromboGenics Completes Patient Enrolment for Phase II Trial of Microplasmin for the Treatment of Diabetic Macular Edema (MIVI II DME)
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
8. Progen Engages Leading CRO to Assist with Phase 3 Trial of PI-88
9. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... National Community Pharmacists Association (NCPA) CEO ... statement in response to a new report ... a number of generic drug costs increased substantially in ... previously expressed by NCPA and underscores the need for ... medications. Moreover, a 2015 survey of 700 community pharmacists ...
(Date:5/28/2015)... NEW YORK , May 27, 2015 ... reached $416 billion in 2014 and with growth of ... on three categories out of pocket: directly on expenditures, ... and drug purchases, and on premiums.  The publisher made ... Healthcare Expenditures in the United States ...
(Date:5/28/2015)... U.S. Department of Justice (DOJ) has entered into a ... to resolve a lawsuit that began more than five ... by two former employees of Orbit.  The whistleblowers alleged ... of Orbit,s top executives, Jake Kilgore , forged ... Medicare for electric wheelchairs.  The lawsuit was brought under ...
Breaking Medicine Technology:NCPA: AARP Drug Pricing Report Reiterates Need for Fair Generic Drug Reimbursements 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 2Report: U.S. Out-of-Pocket Healthcare Spending Reaches $416 Billion 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 2Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 3Electric Wheelchair Sellers Agree To $7.5 Million Settlement Of Whistleblower Case Alleging That Company Forged Medical Records As Part Of Scheme To Defraud Medicare 4
... Oct. 18, 2011 HUYA Bioscience International, a leader ... alliance with the Tianjin International Joint Academy of Biotechnology ... and resources of both parties to accelerate the development ... HUYA is one of the first companies to have ...
... Md., Oct. 18, 2011 TRACE announced today ... Software, available to TRACE members at no cost. ... of recent Foreign Corrupt Practices Act (FCPA) enforcement ... of government officials:  improprieties surrounding corporate gifts, hospitality ...
Cached Medicine Technology:HUYA Bioscience International and Tianjin International Joint Academy of Biotechnology and Medicine Form Alliance 2HUYA Bioscience International and Tianjin International Joint Academy of Biotechnology and Medicine Form Alliance 3TRACE Launches Leading Edge Anti-Bribery Compliance Software 2TRACE Launches Leading Edge Anti-Bribery Compliance Software 3
(Date:5/28/2015)... 2015 The partners of Urgent Care ... present Dr. Alicia Almendral as their chief provider for ... of the newly opened facility’s plan to offer all ... treatments. , Dr. Almendral is a board certified physician ... and cosmetic enhancement techniques. Her areas of expertise include ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Success ... 351(k) Application Process, **FDAnews Webinar**, June 23, 2015 ... [http://www.fdanews.com/BiosimilarsApproval , On June 23, 2015, FDAnews ... two leading intellectual property attorneys from the international ... Strategies for Biosimilars Approval: A Roadmap to the ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 The Boys & ... $2,500 from Horizon Blue Cross Blue Shield of New Jersey ... Natalie Gulbis, the club can receive much more support as ... Acer. , A former Boys & Girls Club member and ... Sacramento, California, Ms. Gulbis has accepted the Horizon Blue Cross ...
(Date:5/28/2015)... AMVETS leaders this week congratulated AMVETS 2015 ... of Newark, Del. AMVETS National Commander Larry Via personally ... $10,000 sweepstakes grand prize. , AMVETS selected the 10 ... the country for prizes ranging from $500 to the ... 21 at the AMVETS National Headquarters in Lanham, MD. ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 As the summer ... to keep cool. It’s important to make safety a top ... sharing some swimming tips. , According to the Centers for ... the United States, not including boating incidents. Additionally, the National ... for children ages 1 to 4. , Amica is ...
Breaking Medicine News(10 mins):Health News:Bella Diosa Med Spa Welcomes Botox Specialist to Yonkers Community 2Health News:FDAnews Announces — Success Strategies for Biosimilars Approval: A Roadmap to the 351(k) Application Process Webinar, June 23, 2015 2Health News:FDAnews Announces — Success Strategies for Biosimilars Approval: A Roadmap to the 351(k) Application Process Webinar, June 23, 2015 3Health News:Golf Pro Natalie Gulbis to Chip in with Horizon Blue Cross Blue Shield of New Jersey to Support Boys & Girls Club of Atlantic City 2Health News:Golf Pro Natalie Gulbis to Chip in with Horizon Blue Cross Blue Shield of New Jersey to Support Boys & Girls Club of Atlantic City 3Health News:AMVETS Announces Summer Sweepstakes Winners 2Health News:Splash! Amica Shares 6 Swimming Safety Tips 2
... The World Health Assembly has given a powerful endorsement ... The strategy brings together crucial elements to reduce childhood ... reduce the 1.4 million adolescent deaths each year. ,Last ... was double the total number of adult deaths from ...
... Recent findings from the University of Hong Kong and,the Shenzhen ... virus from,animals. The findings are observed form a study conducted ... five out of the ten were found to have SARS ... them reported to be sick, thus suggesting that the workers ...
... its border with hard-hit China. ,The first confirmed case of ... Amur river, which forms the frontier with China, came as ... country could contain the disease.,Hu told students in Moscow, at ... strict measures to stop the spread of the deadly virus ...
... people over age 85 have Alzheimer’s disease. Now, researchers ... some postmenopausal women to develop dementia, which is a ... from Wake Forest University studied more than 4,500 postmenopausal ... Initiative. The WHI came to an early end last ...
... 2,000 people possibly exposed to the illness have been ... said Dr. Colin D'Cunha, Ontario's chief medical officer of ... since the outbreak could not control dozens of possible ... the WHO put Canada`s largest city back on its ...
... of a new form of deadly pneumonia is on the ... virus was first detected in South China Asia and is ... World Health Organization the follwing cases of SARS that have ... May 23:// , ,Total number of probable cases: 8,046 , ...
Cached Medicine News:Health News:Hope for 11 million children facing death from illnesses 2Health News:WHO Says Toronto Going Back on SARS-Affected List 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: